XtalPi (2228.HK) HKSE close HKD 9.74 01 Apr 2026: AI growth vs valuation

XtalPi Holdings Ltd (2228.HK) closed at HKD 9.74 on the HKSE on 01 Apr 2026, a move that reflects renewed interest in AI-powered drug discovery. The 1-day change was +4.84%, on volume 98,011,318 shares. This report uses the latest financials, technicals and Meyka AI model output to weigh growth from AI drug discovery against a rich valuation.

2228.HK stock: Market snapshot

XtalPi (2228.HK) ended the session at HKD 9.74, up 4.84% from the prior close of HKD 9.29. Trading range today was HKD 9.20 to HKD 9.80 with volume 98,011,318, above the 50-day average volume of 72,912,633.

The company trades on the HKSE and has a market capitalisation of about HKD 38,773,379,567.00. Investors should note the 50-day moving average at HKD 10.78 and the 200-day at HKD 9.85 for trend context.

Financials and valuation

XtalPi reported EPS of HKD 0.03 and a reported PE of 300.33 on the most recent data. Key ratios show a high price-to-sales of 42.74 and price-to-book of 3.64, signalling premium expectations priced into the stock.

Cash per share stands at HKD 1.64 and book value per share at HKD 2.19. R&D intensity is high at about 70.61% of revenue, while operating cash flow per share is negative HKD 0.03, reflecting heavy investment in product and platform build-out.

Meyka AI rates 2228.HK with a score out of 100

Meyka AI rates 2228.HK with a score out of 100. The proprietary score is 64.38 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly price of HKD 9.26, a quarterly price of HKD 11.76, and a yearly price of HKD 10.66. Against the current price of HKD 9.74, the yearly forecast implies an upside of +9.40%. Forecasts are model-based projections and not guarantees.

Technical picture and trading activity

Momentum indicators show RSI at 37.06, indicating the stock is near neutral-to-oversold territory. MACD is slightly negative with a tiny histogram, while ADX at 22.83 shows a modest trend strength.

Volatility tools put Bollinger middle band at HKD 9.58 and ATR at HKD 0.53. On-chain volume and OBV remain elevated, pointing to sustained investor interest in the AI theme.

Risks and opportunities in AI drug discovery

Opportunity: XtalPi’s AI and automation platform targets the full drug discovery cycle, a structural growth market as pharmaceutical firms adopt AI tools. Success in partnerships and PCC nominations can drive recurring revenue and margin expansion.

Risk: The stock faces valuation pressure. A high PE and thin earnings cushion increase sensitivity to any slowdown in contract wins. Regulatory, clinical execution and competitive risks in AI-drug services are material for investors to monitor.

Price targets and outlook

For tactical planning we set a three-tier price view. A conservative near-term level is HKD 8.00 (bear case), the Meyka base yearly forecast is HKD 10.66 (implied +9.40%), and a bullish three-year target is HKD 14.62 (implied +50.15%).

Scenario planning: if AI contract wins accelerate, upside could track the three-year projection. If growth slips or multiple compresses, downside to the conservative target is plausible. For more context see the company site and ETF holdings analysis source and company filings at XtalPi.

Final Thoughts

Key takeaways: 2228.HK stock closed at HKD 9.74 on 01 Apr 2026, trading above the 200-day average but below the 50-day average. Valuation is rich with a PE near 300.33 and price-to-sales around 42.74, while cash reserves and high R&D spending support the AI-driven growth thesis. Meyka AI’s forecast model projects a one-year price of HKD 10.66, implying an upside of 9.40% from the close. Investors focused on AI stocks should weigh platform adoption milestones and contract cadence against valuation risk. Our Meyka AI grade (B, HOLD) reflects balanced potential and near-term execution risk. Forecasts are model-based projections and not guarantees. Use staged position sizing if adding exposure to XtalPi on the HKSE and track upcoming earnings and partnership updates closely.

FAQs

What drove 2228.HK stock movement today?

2228.HK stock rose to HKD 9.74 as volume picked up to 98,011,318 shares. Traders cited renewed interest in AI drug discovery solutions and technical buying near the 200-day average.

How does Meyka AI grade 2228.HK?

Meyka AI rates 2228.HK with a score of 64.38 out of 100, graded B and suggested HOLD. The grade factors in benchmarks, sector performance, growth metrics and analyst signals.

What is the near-term price forecast for 2228.HK stock?

Meyka AI’s short-term model projects HKD 9.26 monthly and HKD 11.76 quarterly. The one-year model sits at HKD 10.66, implying about +9.40% from the current price.

What are the main risks for 2228.HK investors?

Primary risks for 2228.HK stock include valuation compression, slower-than-expected contract wins, clinical or regulatory setbacks, and rising competition in AI drug discovery services.

Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.